Hartsough EJ - Search Results

1

The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner.

Erkes DA, Field CO, Capparelli C, Tiago M, Purwin TJ, Chervoneva I, Berger AC, Hartsough EJ, Villanueva J, Aplin AE. Erkes DA, et al. Among authors: hartsough ej. Pigment Cell Melanoma Res. 2019 Sep;32(5):687-696. doi: 10.1111/pcmr.12788. Epub 2019 May 20. Pigment Cell Melanoma Res. 2019. PMID: 31063649 Free PMC article.

2

Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.

Basile KJ, Le K, Hartsough EJ, Aplin AE. Basile KJ, et al. Among authors: hartsough ej. Pigment Cell Melanoma Res. 2014 May;27(3):479-84. doi: 10.1111/pcmr.12218. Epub 2014 Feb 10. Pigment Cell Melanoma Res. 2014. PMID: 24422853 Free PMC article.

3

Of Mice and Melanoma: PDX System for Modeling Personalized Medicine.

Hartsough EJ, Aplin AE. Hartsough EJ, et al. Clin Cancer Res. 2016 Apr 1;22(7):1550-2. doi: 10.1158/1078-0432.CCR-15-3054. Epub 2016 Feb 3. Clin Cancer Res. 2016. PMID: 26842234 Free PMC article.

4

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo.

Hartsough EJ, Kugel CH 3rd, Vido MJ, Berger AC, Purwin TJ, Goldberg A, Davies MA, Schiewer MJ, Knudsen KE, Bollag G, Aplin AE. Hartsough EJ, et al. Mol Cancer Ther. 2018 Jan;17(1):84-95. doi: 10.1158/1535-7163.MCT-17-0705. Epub 2017 Nov 13. Mol Cancer Ther. 2018. PMID: 29133617 Free PMC article.

5

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.

Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, Berger AC, Hartsough EJ, Rodeck U, Alnemri ES, Aplin AE. Erkes DA, et al. Among authors: hartsough ej. Cancer Discov. 2020 Feb;10(2):254-269. doi: 10.1158/2159-8290.CD-19-0672. Epub 2019 Dec 3. Cancer Discov. 2020. PMID: 31796433 Free PMC article.

6

Resistance to RAF inhibitors revisited.

Hartsough E, Shao Y, Aplin AE. Hartsough E, et al. J Invest Dermatol. 2014 Feb;134(2):319-325. doi: 10.1038/jid.2013.358. Epub 2013 Oct 10. J Invest Dermatol. 2014. PMID: 24108405 Free PMC article. Review.

7

A STATement on vemurafenib-resistant melanoma.

Hartsough EJ, Aplin AE. Hartsough EJ, et al. J Invest Dermatol. 2013 Aug;133(8):1928-9. doi: 10.1038/jid.2013.136. J Invest Dermatol. 2013. PMID: 23856932 Free PMC article.

8

In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors.

Basile KJ, Abel EV, Dadpey N, Hartsough EJ, Fortina P, Aplin AE. Basile KJ, et al. Among authors: hartsough ej. Cancer Res. 2013 Dec 1;73(23):7101-10. doi: 10.1158/0008-5472.CAN-13-1628. Epub 2013 Oct 11. Cancer Res. 2013. PMID: 24121492 Free PMC article.

9

Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma.

Hartsough EJ, Basile KJ, Aplin AE. Hartsough EJ, et al. Mol Cancer Res. 2014 May;12(5):795-802. doi: 10.1158/1541-7786.MCR-13-0581. Epub 2014 Feb 11. Mol Cancer Res. 2014. PMID: 24520098 Free PMC article.

10

Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor.

Kugel CH 3rd, Hartsough EJ, Davies MA, Setiady YY, Aplin AE. Kugel CH 3rd, et al. Among authors: hartsough ej. Cancer Res. 2014 Aug 1;74(15):4122-32. doi: 10.1158/0008-5472.CAN-14-0464. Epub 2014 Jul 17. Cancer Res. 2014. PMID: 25035390 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24 results

Search Page